El segundo trimestre se destacó por la aprobación de Zepzelca y nuestro fuerte lanzamiento posterior, que se logró dentro de los seis meses posteriores al cierre del acuerdo de licencia con PharmaMar".
Zepzelca™ (lurbinectedin):
- In June 2020, Zepzelca received accelerated approval by FDA for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
- In July 2020, the company launched Zepzelca in the U.S. and the National Comprehensive Cancer Network (NCCN) added Zepzelca to the Clinical Practice Guidelines in Oncology for SCLC as a preferred treatment in patients who relapse in six months or less after prior systemic therapy and as a recommended regimen in patients who relapse more than six months after prior systemic therapy.
- All contracts with distributors and GPOs were in place at launch.
- The company is experiencing strong initial physician reception and uptake of Zepzelca across academic and community accounts and the sales force is actively engaging with target prescribers through live and virtual interactions.
